These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21478906)

  • 1. β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.
    Morello V; Cabodi S; Sigismund S; Camacho-Leal MP; Repetto D; Volante M; Papotti M; Turco E; Defilippi P
    Oncogene; 2011 Sep; 30(39):4087-96. PubMed ID: 21478906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
    Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 upregulates β1 integrin expression via the E prostanoid 1 receptor/nuclear factor κ-light-chain-enhancer of activated B cells pathway in non-small-cell lung cancer cells.
    Bai X; Yang Q; Shu W; Wang J; Zhang L; Ma J; Xia S; Zhang M; Cheng S; Wang Y; Leng J
    Mol Med Rep; 2014 May; 9(5):1729-36. PubMed ID: 24584670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
    Kanda R; Kawahara A; Watari K; Murakami Y; Sonoda K; Maeda M; Fujita H; Kage M; Uramoto H; Costa C; Kuwano M; Ono M
    Cancer Res; 2013 Oct; 73(20):6243-53. PubMed ID: 23872583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Ju L; Zhou C; Li W; Yan L
    J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
    Ju L; Zhou C
    Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional expression of the voltage-gated Na⁺-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells.
    Campbell TM; Main MJ; Fitzgerald EM
    J Cell Sci; 2013 Nov; 126(Pt 21):4939-49. PubMed ID: 23986482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
    Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
    Shen H; Yuan Y; Sun J; Gao W; Shu YQ
    Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation.
    Liu B; Su Y; Li T; Yuan W; Mo X; Li H; He Q; Ma D; Han W
    Oncotarget; 2015 Dec; 6(38):41092-107. PubMed ID: 26528697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas.
    Tysnes BB; Haugland HK; Bjerkvig R
    Invasion Metastasis; 1997; 17(5):270-80. PubMed ID: 9876221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells.
    Li L; Qi L; Liang Z; Song W; Liu Y; Wang Y; Sun B; Zhang B; Cao W
    Int J Mol Med; 2015 Jul; 36(1):113-22. PubMed ID: 26005723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of integrin α3β1 expression induces proliferation and migration of non-small cell lung cancer cells.
    Yoon HJ; Cho YR; Joo JH; Seo DW
    Oncol Rep; 2013 Feb; 29(2):662-8. PubMed ID: 23233127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
    Liu L; Shao X; Gao W; Zhang Z; Liu P; Wang R; Huang P; Yin Y; Shu Y
    FEBS J; 2012 Oct; 279(20):3800-12. PubMed ID: 22883469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.